Esmolol

Generic Name: Esmolol

Brand Names: Brevibloc

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₅NO_₄

CAS Number: 81147-92-4

Unique Ingredient Identifier: MDY902UXSR

Background: Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.

The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.

Indication: For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.

Associated Conditions: Hypertension, Tachycardia, Abnormal ventricular rate, Heart rate abnormal

Clinical Trials

Effects of Adrenergic Drugs on the Fluid Balance During Surgery

Phase 1

Completed

Conditions: Ovarian Cyst

Interventions: Drug: Esmolol administration
Drug: Phenylephrine infusion
Drug: Lactated Ringer´s solution

First Posted Date: 2011-09-09

Last Posted Date: 2011-09-09

Lead Sponsor: Sodertalje Hospital

Target Recruit Count: 60

Registration Number: NCT01431612

Locations: 🇨🇳
Department of Anesthesiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol

Phase 4

Terminated

Conditions: Hypertension
Vascular Disease
Angina
Cardiac Disease

Interventions: Drug: Metoprolol
Drug: Esmolol

First Posted Date: 2011-07-28

Last Posted Date: 2015-04-21

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 20

Registration Number: NCT01404767

Locations: 🇨🇦
University Heatlh Network, Toronto General Hopsital, Toronto, Ontario, Canada

Genetic Determinants of Hemodynamic Response to Esmolol

Not Applicable

Conditions: Decrease in Heart Rate Below Baseline Value

Interventions: Drug: esmolol

First Posted Date: 2011-07-06

Last Posted Date: 2011-07-06

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 100

Registration Number: NCT01388036

Locations: 🇮🇱
Hadassah Hebrew University Medical Center, Jerusalem, Israel

Controlling Hyperadrenergic Activity in Neurologic Injury

Phase 1

Withdrawn

Conditions: Dysautonomia
Traumatic Brain Injury

Interventions: Drug: Esmolol
Drug: Propranolol

First Posted Date: 2011-04-28

Last Posted Date: 2017-04-20

Lead Sponsor: Johns Hopkins University

Registration Number: NCT01343329

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

Phase 2

Completed

Conditions: Healthy Volunteers
Pharmacokinetics/Dynamics Study

Interventions: Drug: AOP200704
Drug: Esmolol hydrochloride, infusion

First Posted Date: 2011-03-11

Last Posted Date: 2012-07-19

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 16

Registration Number: NCT01313143

Locations: 🇨🇿
AOP contract research facility, Pilsen, Czech Republic

Non-opioid Analgesia for Fast-track Surgery

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: Esmolol
Drug: Remifentanil

First Posted Date: 2011-01-13

Last Posted Date: 2013-03-27

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 40

Registration Number: NCT01275911

Locations: 🇨🇦
Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada

Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage

Not Applicable

Withdrawn

Conditions: Subarachnoid Hemorrhage

Interventions: Drug: Esmolol

First Posted Date: 2010-11-02

Last Posted Date: 2015-01-08

Lead Sponsor: University of Michigan

Registration Number: NCT01232400

Locations: 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States

Heart Rate Control With Esmolol in Septic Shock

Phase 2

Completed

Conditions: Septic Shock

Interventions: Other: control
Drug: esmolol

First Posted Date: 2010-11-01

Last Posted Date: 2013-01-24

Lead Sponsor: Andrea Morelli

Target Recruit Count: 154

Registration Number: NCT01231698

Locations: 🇮🇹
Department of Anesthesiology and Intensive care of the University of Rome La Sapienza, Rome, Italy

Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: esmolol
Drug: nitroglycerin

First Posted Date: 2010-10-01

Last Posted Date: 2019-03-01

Lead Sponsor: Loma Linda University

Target Recruit Count: 70

Registration Number: NCT01212874

Locations: 🇺🇸
Loma Linda University, Loma Linda, California, United States

Esmolol for Treatment of Perioperative Tachycardia

Phase 3

Terminated

Conditions: High-risk, Non-cardiovascular Surgeries

Interventions: Drug: Esmolol

First Posted Date: 2010-09-24

Last Posted Date: 2014-12-12

Lead Sponsor: Duke University

Target Recruit Count: 76

Registration Number: NCT01208402

Locations: 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy